[go: up one dir, main page]

LT3784666T - Antiproliferaciniai junginiai ir jų panaudojimas - Google Patents

Antiproliferaciniai junginiai ir jų panaudojimas

Info

Publication number
LT3784666T
LT3784666T LTEPPCT/US2019/028607T LTUS2019028607T LT3784666T LT 3784666 T LT3784666 T LT 3784666T LT US2019028607 T LTUS2019028607 T LT US2019028607T LT 3784666 T LT3784666 T LT 3784666T
Authority
LT
Lithuania
Prior art keywords
antiproliferation
compounds
antiproliferation compounds
Prior art date
Application number
LTEPPCT/US2019/028607T
Other languages
English (en)
Inventor
Henry Yu
Michael Clark
Guy Bemis
Michael Boyd
Kishan Chandupatla
Philip Collier
Hongbo Deng
Huijun DONG
Warren Dorsch
Russell Hoover
Mac JOHNSON
Shashank KULKARNI
Marina PENNEY
Steven Ronkin
Darin TAKEMOTO
Qing Tang
Nathan Waal
Tiansheng Wang
David J. Lauffer
Pan Li
Original Assignee
Merck Patent Gmbh
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh, Vertex Pharmaceuticals Incorporated filed Critical Merck Patent Gmbh
Publication of LT3784666T publication Critical patent/LT3784666T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/113Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
LTEPPCT/US2019/028607T 2018-04-24 2019-04-23 Antiproliferaciniai junginiai ir jų panaudojimas LT3784666T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862661719P 2018-04-24 2018-04-24
PCT/US2019/028607 WO2019209759A1 (en) 2018-04-24 2019-04-23 Antiproliferation compounds and uses thereof

Publications (1)

Publication Number Publication Date
LT3784666T true LT3784666T (lt) 2022-06-10

Family

ID=66655429

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2019/028607T LT3784666T (lt) 2018-04-24 2019-04-23 Antiproliferaciniai junginiai ir jų panaudojimas

Country Status (27)

Country Link
US (4) US10815225B2 (lt)
EP (2) EP3784666B1 (lt)
JP (2) JP7304892B2 (lt)
KR (1) KR102813581B1 (lt)
CN (1) CN112236428B (lt)
AR (1) AR114496A1 (lt)
AU (1) AU2019261308B2 (lt)
BR (1) BR112020020940A2 (lt)
CA (1) CA3098335A1 (lt)
CY (1) CY1125433T1 (lt)
DK (2) DK3784666T3 (lt)
ES (2) ES2919572T3 (lt)
FI (1) FI4043460T3 (lt)
HR (2) HRP20241163T1 (lt)
HU (2) HUE067936T2 (lt)
IL (2) IL301501B2 (lt)
LT (1) LT3784666T (lt)
MX (1) MX2020011089A (lt)
PL (2) PL3784666T3 (lt)
PT (2) PT3784666T (lt)
RS (1) RS63281B1 (lt)
SG (1) SG11202009500QA (lt)
SI (1) SI3784666T1 (lt)
SM (1) SMT202200308T1 (lt)
TW (1) TWI813673B (lt)
WO (1) WO2019209759A1 (lt)
ZA (1) ZA202006071B (lt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3784666T (pt) 2018-04-24 2022-06-06 Merck Patent Gmbh Compostos antiproliferação e utilizações dos mesmos
WO2020010451A1 (en) * 2018-07-10 2020-01-16 Trillium Therapeutics Inc. Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists
WO2020236834A1 (en) * 2019-05-20 2020-11-26 Seshadri Raju Modified z stents for iliac vein stenting
AU2020406139A1 (en) 2019-12-20 2022-06-30 Bayer Aktiengesellschaft Substituted thiophene carboxamides, thiophene carboxylic acids and derivatives thereof
WO2024073502A1 (en) * 2022-09-28 2024-04-04 Accutar Biotechnology Inc. Heterocyclic compounds as e3 ligase inhibitors
WO2025223536A1 (zh) * 2024-04-26 2025-10-30 正大天晴药业集团股份有限公司 稠合双环化合物及其用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
DE19840028A1 (de) 1998-09-02 2000-03-09 Max Planck Gesellschaft Nucleinsäuremoleküle codierend Enzyme, die Fructosyltransferaseaktivität besitzen, und deren Verwendung
UA72290C2 (uk) 1999-12-10 2005-02-15 Пфайзер Продактс Інк. СПОЛУКИ ПІРОЛО[2.3-d]ПІРИМІДИНУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ (ВАРІАНТИ), СПОСІБ ІНГІБУВАННЯ ПРОТЕЇНКІНАЗ АБО JANUS КІНАЗИ 3 (ВАРІАНТИ)
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
EP1389617B1 (en) 2001-04-27 2007-01-03 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and antitumor agent containing the same as active ingredient
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
EP2055310B1 (en) 2002-08-14 2015-12-16 Silence Therapeutics GmbH Protein kinase N beta for the diagnosis and the treatment of late stage tumor
BRPI0409063A (pt) 2003-04-03 2006-03-28 Semafore Pharmaceuticals Inc pró medicamentos de inibidor de pi-3 cinase
BRPI0410870A (pt) 2003-05-30 2006-07-04 Gemin X Biotechnologies Inc compostos trieterocìclicos, composições, e métodos para tratar cáncer ou doenças virais
CN100577680C (zh) 2003-07-03 2010-01-06 宾夕法尼亚大学理事会 对Syk激酶表达的抑制
RS55546B1 (sr) 2004-05-13 2017-05-31 Icos Corp Hinazolinoni kao inhibitori humane fosfatidilonozitol 3-delta kinaze
EP2161275A1 (en) 2005-01-19 2010-03-10 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
KR101533268B1 (ko) 2005-05-12 2015-07-03 애브비 바하마스 리미티드 아폽토시스 촉진제
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
EP1931645B1 (en) 2005-10-07 2014-07-16 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
NZ592990A (en) 2005-11-01 2013-01-25 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
DK3184526T3 (en) 2005-12-13 2019-01-14 Incyte Holdings Corp PYRROLO [2,3-D] PYRIMIDINE DERIVATIVES AS A JANUS-KINASE INHIBITOR
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
BRPI0710874A2 (pt) 2006-04-26 2012-02-14 Hoffmann La Roche compostos de tienopirimidina, processos de produção dos referidos compostos, composições farmacêuticas contendo os mesmos, kit, produto, e usos dos compostos
PT2201840E (pt) 2006-09-22 2012-02-14 Pharmacyclics Inc Inibidores da tirosina quinase de bruton
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
CN101861313B (zh) 2007-03-12 2014-06-04 Ym生物科学澳大利亚私人有限公司 苯基氨基嘧啶化合物及其用途
WO2008118802A1 (en) 2007-03-23 2008-10-02 Regents Of The University Of Minnesota Therapeutic compounds
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
BRPI0909040B8 (pt) 2008-03-11 2021-05-25 Incyte Holdings Corp derivados de azetidina e ciclobutano, seus usos, e composição
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
DE102008031517A1 (de) * 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
EP2318377B1 (en) 2008-07-31 2013-08-21 Genentech, Inc. Pyrimidine compounds, compositions and methods of use
AR076014A1 (es) * 2009-04-02 2011-05-11 Sanofi Aventis Derivados de 3- (1,4) oxazepan -4-pirimidona
BR112012012905A2 (pt) * 2009-12-04 2017-03-01 Hoffmann La Roche derivados de difenil azepina como inibidores da reabsorção de monoamina
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CN107207482A (zh) * 2015-02-13 2017-09-26 默克专利股份公司 用于治疗癌症的嘧啶衍生物
PT3784666T (pt) 2018-04-24 2022-06-06 Merck Patent Gmbh Compostos antiproliferação e utilizações dos mesmos

Also Published As

Publication number Publication date
US11440907B1 (en) 2022-09-13
CN112236428B (zh) 2025-04-01
FI4043460T3 (fi) 2025-05-09
IL301501B1 (en) 2024-06-01
HRP20220710T1 (hr) 2022-07-22
CA3098335A1 (en) 2019-10-31
RS63281B1 (sr) 2022-06-30
US20230150993A1 (en) 2023-05-18
AU2019261308A1 (en) 2020-10-22
KR102813581B1 (ko) 2025-05-29
US20190322658A1 (en) 2019-10-24
DK4043460T3 (da) 2024-08-26
HUE067936T2 (hu) 2024-11-28
PL3784666T3 (pl) 2022-07-18
IL301501A (en) 2023-05-01
TWI813673B (zh) 2023-09-01
US20250188070A1 (en) 2025-06-12
TW202012400A (zh) 2020-04-01
DK3784666T3 (da) 2022-06-20
CN112236428A (zh) 2021-01-15
ES2987356T3 (es) 2024-11-14
EP3784666A1 (en) 2021-03-03
IL278142B2 (en) 2023-11-01
KR20210005151A (ko) 2021-01-13
SG11202009500QA (en) 2020-11-27
MX2020011089A (es) 2020-11-06
AU2019261308B2 (en) 2022-09-08
PT4043460T (pt) 2024-09-10
JP7304892B2 (ja) 2023-07-07
PL4043460T3 (pl) 2024-10-28
US12195453B2 (en) 2025-01-14
AR114496A1 (es) 2020-09-09
HUE058746T2 (hu) 2022-09-28
JP2021522242A (ja) 2021-08-30
US10815225B2 (en) 2020-10-27
ZA202006071B (en) 2024-01-31
HRP20241163T1 (hr) 2024-11-22
IL301501B2 (en) 2024-10-01
CY1125433T1 (el) 2025-05-09
ES2919572T3 (es) 2022-07-27
IL278142A (en) 2020-11-30
IL278142B1 (en) 2023-07-01
EP4043460B1 (en) 2024-06-05
EP4043460A1 (en) 2022-08-17
BR112020020940A2 (pt) 2021-03-02
SI3784666T1 (sl) 2022-07-29
WO2019209759A1 (en) 2019-10-31
SMT202200308T1 (it) 2022-09-14
EP3784666B1 (en) 2022-03-16
PT3784666T (pt) 2022-06-06
JP2023101824A (ja) 2023-07-21

Similar Documents

Publication Publication Date Title
IL285177A (en) compounds and their use
IL273236A (en) Pyrazolopyrimidine compounds and their uses
IL277502A (en) Compounds and uses for them
IL286497A (en) compounds and their use
IL294052B1 (en) Fluoroalkyl oxadiazoles and their uses
GB201803568D0 (en) Novel compounds and uses
IL278142A (en) Antiproliferative compounds and their uses
IL272055A (en) 8,1-naphthyridinone compounds and their uses
IL276753A (en) Epibrotic compounds, their devices and uses
SG11202108079RA (en) Compounds and uses thereof
IL291499A (en) Azaquinoline compounds and their uses
ZA202105752B (en) Haloallylamine compounds and application thereof
IL284764A (en) compounds and their uses
IL279483A (en) Cyanotriazole compounds and their uses
IL287503A (en) Thio-semicarbazide compounds and their use
IL280644A (en) Magnesium serine compound and its use
GB201812078D0 (en) Novel compounds and their uses
GB201801102D0 (en) New compounds and uses
IL280369A (en) Myokines and their uses
GB201806349D0 (en) New compounds and uses
ZA202201239B (en) Aminothiolester compounds and uses thereof
IL283540A (en) Dock1 inhibitory compound and use thereof
GB201810667D0 (en) New compounds and uses
HK40043702A (en) Cyanotriazole compounds and uses thereof
HK40046130A (en) Compounds and uses thereof